title: Early intervention with liraglutide improves glucose tolerance without affecting islet microcirculation in young Goto-Kakizaki rats.
abstract: Liraglutide, an analog of glucagon-like peptide-1 (GLP-1), is an effective anti-diabetic agent with few side effects. Since native GLP-1 exerts vascular effects, we investigated changes in pancreatic islet blood flow using a non-radioactive microsphere technique, as well as insulin concentration and glucose tolerance after 17 day treatment with liraglutide in 6-week-old Goto-Kakizaki (GK) rats. Compared to saline-treated control GK rats, liraglutide limited body weight gain, decreased glycemia, improved glucose tolerance and lowered serum insulin concentration. Neither pancreatic or islet blood flow, nor pancreatic insulin content, was affected by liraglutide treatment. We conclude that early intervention with liraglutide decreases glycemia and improves glucose tolerance, thus halting the natural progression towards diabetes, without affecting islet microcirculation or pancreatic insulin content in young female GK rats.
authors.affiliation: Fudan University, Department of Geriatrics, Zhongshan Hospital, 180 Fenglin Road, Shanghai 200032, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Wu
authors.forename: Anna
authors.initials: A
authors.lastname: Olverling
authors.forename: Liselotte
authors.initials: L
authors.lastname: Fransson
authors.forename: Henrik
authors.initials: H
authors.lastname: Ortsäter
authors.forename: Camilla
authors.initials: C
authors.lastname: Kappe
authors.forename: Xin
authors.initials: X
authors.lastname: Gao
authors.forename: Ake
authors.initials: A
authors.lastname: Sjöholm
mesh_terms: D000367:Age Factors; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism / Q000473:pathology; D018450:Disease Progression; D061345:Early Medical Intervention; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000494:pharmacology; D005951:Glucose Tolerance Test / Q000379:methods; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000097:blood / Q000378:metabolism; D007515:Islets of Langerhans / Q000098:blood supply* / Q000187:drug effects; D000069450:Liraglutide; D008297:Male; D008833:Microcirculation; D008863:Microspheres; D051381:Rats; D015431:Weight Loss
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1